- Home
- ETJ vs PCRX Comparison
ETJ vs PCRX Comparison
Compare ETJ & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETJ
- PCRX
- Stock Information
- Founded
- ETJ 2007
- PCRX 2006
- Country
- ETJ United States
- PCRX United States
- Employees
- ETJ N/A
- PCRX N/A
- Industry
- ETJ Finance Companies
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ETJ Finance
- PCRX Health Care
- Exchange
- ETJ Nasdaq
- PCRX Nasdaq
- Market Cap
- ETJ 623.9M
- PCRX 604.7M
- IPO Year
- ETJ N/A
- PCRX 2011
- Fundamental
- Price
- ETJ $9.16
- PCRX $21.50
- Analyst Decision
- ETJ
- PCRX Buy
- Analyst Count
- ETJ 0
- PCRX 10
- Target Price
- ETJ N/A
- PCRX $27.60
- AVG Volume (30 Days)
- ETJ 175.6K
- PCRX 779.4K
- Earning Date
- ETJ 01-01-0001
- PCRX 02-27-2025
- Dividend Yield
- ETJ 8.30%
- PCRX N/A
- EPS Growth
- ETJ N/A
- PCRX N/A
- EPS
- ETJ N/A
- PCRX N/A
- Revenue
- ETJ N/A
- PCRX $694,957,000.00
- Revenue This Year
- ETJ N/A
- PCRX $4.83
- Revenue Next Year
- ETJ N/A
- PCRX $2.16
- P/E Ratio
- ETJ N/A
- PCRX N/A
- Revenue Growth
- ETJ N/A
- PCRX 4.40
- 52 Week Low
- ETJ $7.20
- PCRX $11.16
- 52 Week High
- ETJ $8.47
- PCRX $34.01
- Technical
- Relative Strength Index (RSI)
- ETJ 46.02
- PCRX 60.46
- Support Level
- ETJ $9.12
- PCRX $18.18
- Resistance Level
- ETJ $9.30
- PCRX $22.36
- Average True Range (ATR)
- ETJ 0.12
- PCRX 0.97
- MACD
- ETJ -0.02
- PCRX 0.11
- Stochastic Oscillator
- ETJ 36.83
- PCRX 53.46
About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.